|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM199033714 |
| 003 |
DE-627 |
| 005 |
20231223213842.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231223s2010 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2010.04.019
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0663.xml
|
| 035 |
|
|
|a (DE-627)NLM199033714
|
| 035 |
|
|
|a (NLM)20570567
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Bontkes, Hetty J
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Attenuation of invariant natural killer T-cell anergy induction through intradermal delivery of alpha-galactosylceramide
|
| 264 |
|
1 |
|c 2010
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 30.08.2010
|
| 500 |
|
|
|a Date Revised 06.08.2010
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright 2010 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a CD1d restricted, alpha-galactosylceramide (alphaGC) responsive invariant (i)NKT cells positively regulate immune responses. Both intravenous and intradermal administered alphaGC are known to activate iNKT cells. iNKT cells become unresponsive to a second intravenous alphaGC injection, whereas no data are available regarding potential anergy upon intradermal administration. Here, comparative analysis of two intradermal versus two intravenous injections in mice demonstrated that iNKT cell anergy was prevented by intradermal injection and when combined with a vaccine, superior tumor protection afforded by intradermally administered alphaGC. Moreover, human skin dendritic cells (DC) took up intradermally injected alphaGC and activated iNKT cells upon migration, while iNKT cells in human skin-draining lymph nodes expanded in response to alphaGC presented either by exogenously added DC or by CD1d positive antigen presenting cells in the lymph nodes. In conclusion, glycolipids such as alphaGC may greatly improve the efficacy of skin immunization strategies, targeting cutaneous and lymph node DC
|
| 650 |
|
4 |
|a Comparative Study
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Adjuvants, Immunologic
|2 NLM
|
| 650 |
|
7 |
|a Cytokines
|2 NLM
|
| 650 |
|
7 |
|a Galactosylceramides
|2 NLM
|
| 650 |
|
7 |
|a alpha-galactosylceramide
|2 NLM
|
| 650 |
|
7 |
|a Ovalbumin
|2 NLM
|
| 650 |
|
7 |
|a 9006-59-1
|2 NLM
|
| 700 |
1 |
|
|a Moreno, María
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hangalapura, Basav
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lindenberg, Jelle J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a de Groot, Jan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lougheed, Sinéad
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a van der Vliet, Hans J J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a van den Eertwegh, Alfons J M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a de Gruijl, Tanja D
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a von Blomberg, B Mary E
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Scheper, Rik J
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 136(2010), 3 vom: 15. Sept., Seite 364-74
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:136
|g year:2010
|g number:3
|g day:15
|g month:09
|g pages:364-74
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2010.04.019
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 136
|j 2010
|e 3
|b 15
|c 09
|h 364-74
|